Madrigal Pharmaceuticals, Inc.
MDGL
$421.90
$9.672.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 72.18% | 50.36% | 47.04% | -8.33% | -77.12% |
| Total Depreciation and Amortization | 61.80% | 158.93% | 155.63% | 120.74% | 111.90% |
| Total Amortization of Deferred Charges | -21.40% | -33.44% | -35.99% | -28.78% | -14.80% |
| Total Other Non-Cash Items | 6.95% | 5.17% | 19.40% | 37.76% | 122.40% |
| Change in Net Operating Assets | -290.23% | -67.65% | -485.42% | 6,100.00% | -597.94% |
| Cash from Operations | 65.13% | 40.40% | -30.72% | 21.12% | -79.19% |
| Capital Expenditure | -- | -- | 81.18% | -129.79% | -89.86% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 139.24% | 66.53% | 86.77% | -498.93% | -3,229.70% |
| Cash from Investing | 139.20% | 67.13% | 86.76% | -503.18% | -3,171.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.70% | -98.49% | -95.88% | 60.30% | 378.93% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -98.70% | -98.49% | -95.88% | -61.89% | 212.42% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 102.07% | -84.00% | -450.41% | -1,629.83% | -240.39% |